Pro Forma Loss Per Share. Represents the net loss per share calculated using the historical weighted average shares outstanding, and the issuance of additional shares in connection with the Business Combination, assuming the shares were outstanding since January 1, 2023. As the Business Combination and related transactions are being reflected as if they had occurred as of January 1, 2023, the calculation of weighted average shares outstanding for basic and diluted net loss per share assumes that the shares issuable relating to the Business Combination have been outstanding for the year ended December 31, 2023. (in thousands, except share and per share data) Year ended December 31, 2023 Pro forma net loss $ (78,071 ) Weighted-average shares outstanding, basic and diluted (1)(2) 133,950,115 Net loss per share attributable to common stockholders, basic and diluted $ (0.58 )
Pro Forma Loss Per Share. The Pro Forma basic and diluted historical net loss per share use the historical amounts for ISS Group, Inc adjusted by the impact of the March Systems acquisition. This impact includes March Systems historical net income for the periods, the impact of purchase accounting adjustments and the shares of Common Stock issued in connection with the acquisition. Additionally, these pro forma consolidated statements of operation reflect adjustments to the pro forma net loss per share amounts reflected in the ISS historical consolidated statements of operations. The per share amounts were computed for the historical ISS statements by dividing its net losses by the number of shares of common Stock outstanding plus the conversion of the 3,650,000 shares of Series A and 2,087,000 shares of Series B Redeemable, Convertible Preferred Stock into 5,737,000 share of Common Stock which occurred upon consummation of the Company's initial public offering in March 1998. These pro forma financial statements adjust such net loss and weighted average share amounts for March Systems historical net income for the periods, the impact of purchase accounting adjustments and the shares of Common Stock issued in connection with the acquisition.
Pro Forma Loss Per Share. The pro forma combined basic and diluted earnings per share have been adjusted to reflect the pro forma net loss for the year ended December 31, 2022, and the nine months ended September 30, 2023. In addition, the number of shares used in calculating the pro forma combined basic and diluted net loss per share has been adjusted to reflect the total number of shares of common stock of the combined company that is outstanding as of the closing date (see Note 5 adjustment K). For the year ended December 31, 2022 and the nine months ended September 30, 2023, the pro forma weighted average shares outstanding and proforma net loss per share has been calculated as follows: (In thousands, except per share data) Nine Months ended September 30, 2023 Year ended December 31, 2022 Pro forma net loss $ (126,497 ) $ (242,978 ) Total weighted average shares outstanding 288,545 287,882 Pro forma basic net loss per share - basic and diluted*** (0.44 ) (0.84 ) *** The following potentially dilutive common shares were excluded from the computations of diluted net loss per share for the periods presented because including them would have been anti-dilutive: Nine Months ended September 30, 2023 Year ended December 31, 2022 Replacement Stock Options and RSUs issued as part of the Merger 30,901 30,901 New stock options and PSUs issued for executives as part of the Merger 400 400 Replacement awards for the Palamedrix founders issued as part of the Merger 588 588 Standard BioTools' Stock options, RSUs, and performance stock awards 16,872 15,455 Standard BioTools’ Series B Preferred Stock 75,164 75,164 Standard BioTools’ 2019 Convertible Notes 18,966 18,966 Standard BioTools’ 2019 Convertible Notes potential make-whole shares 2,181 4,741 Standard BioTools’ 2014 Convertible Notes 10 10 SomaLogic Public warrants and private placement warrants 10,533 10,533 Total anti-dilutive shares 155,615 156,758
Pro Forma Loss Per Share. The following table sets forth the computation of pro forma basic and diluted loss per share for the nine months ended February 28, 2017 and for the year ended May 31, 2016: Nine months ended February 28, 2017 Year ended May 31, 2016 Numerator Pro-Forma net loss for the period $ (7,294,262 ) $ (6,248,289 ) Denominator Basic and Diluted – weighted average number of shares outstanding 102,822,723 78,327,306 Pro-Forma Loss Per Share – Basic and Diluted $ (0.07 ) $ (0.08 )
Pro Forma Loss Per Share. Historical Tilray basic weighted average shares at December 31, 2020 126,041,710 Adjustment for warrants exercised at Measurement Date (note 3, note 4H) 6,290,000 Incremental shares issued in merger transaction (note 4B) 265,504,347 Pro forma combined basic and diluted weighted average shares 397,836,057 On a pro forma basis, the combined company incurred a net loss for the year ended December 31, 2020. As such, all potential shares are excluded from the calculation of pro forma diluted loss per share because they are anti-dilutive.
Pro Forma Loss Per Share. Shares used in computing pro forma combined basic and diluted loss per share are based on the weighted average outstanding shares of Rovi common stock and common stock equivalents for the periods presented, plus the
